<DOC>
	<DOCNO>NCT00003009</DOCNO>
	<brief_summary>RATIONALE : Interleukin-2 may stimulate person 's white blood cell kill cancer cell . Giving interleukin-2 different way may kill cancer cell . PURPOSE : Phase I trial study effectiveness inhale interleukin-2 treating patient metastatic unresectable cancer .</brief_summary>
	<brief_title>Inhaled Interleukin-2 Treating Patients With Metastatic Unresectable Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Define safe tolerance inhale interleukin-2 ( IL-2 ) administer twice day . II . Determine blood level IL-2 whether detectable stimulation immune cell patient receive inhalation IL-2 . III . Determine whether shrinkage pulmonary lesion patient treat study . OUTLINE : This two arm , escalate dose study interleukin-2 ( IL-2 ) . In Arm I patient cohorts 3-6 administered daily inhalation IL-2 15 minute Monday Friday 4 consecutive week . At least 3 patient treat dose level , patient cohort observe least 2 week escalate high dose absence dose limit toxicity . Escalation stop maximum tolerate dose ( MTD ) determine . In Arm II initial dose 25 percent MTD determine Arm I administer inhalation twice daily Monday Friday 4 week . Subsequent patient cohort receive dos escalate 33 percent previous dose level . Responding patient continue treatment cycle 4 week 2 week rest develop progressive disease intolerable toxicity . Stable patient may stay treatment maximum 4 cycle . PROJECTED ACCRUAL : A minimum 12-15 maximum 30 patient accrue study .</detailed_description>
	<mesh_term>Aldesleukin</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm unresectable metastatic cancer Confirmed biopsy fine needle aspiration Tumors must predominantly involve lung Measurable evaluable disease No lymphoma leukemias No AIDS associate Kaposi 's Sarcoma No uncontrolled brain metastasis PATIENT CHARACTERISTICS : Age : 18 Performance status : SWOG 01 Life expectancy : At least 3 month Hematopoietic : WBC least 4,000/mm3 Platelet count within normal limit Hepatic : Bilirubin great 2 time normal Renal : Creatinine great 2.0 mg/dL Cardiovascular : Adequate cardiovascular system NYHA Class 0 I No uncontrolled cardiac arrhythmia Pulmonary : FEV1 least 65 % predict FVC least 65 % predict No asthma bronchial obstruction would prevent delivery IL2 lobe lung Other : HIV negative No medical psychological criterion would make patient unable tolerate treatment Not pregnant nursing Adequate contraception require fertile patient PRIOR CONCURRENT THERAPY : Biologic therapy : No prior interleukin2 Prior biologic response therapy allow No chronic use immunosuppressive medicine Chemotherapy : Prior chemotherapy allow Endocrine therapy : No chronic steroid use Prior hormonal therapy allow Radiotherapy : No prior concurrent radiotherapy except palliative area painful metastasis outside lung Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>